CMT-133 not checked

Clement Therapeutics, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Main trialPhase 1
“This study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CMT-133 in healthy adult participants after single or multiple doses. It is a randomized, double-blind, placebo-controlled, SAD and MAD study, which will be conducted in Parts A and B, respectively. CMT-133 will be administered via SC injection. Placebo will consist of normal saline administered via the same route (SC) and in a manner indistinguishable from active treatment.”In the company’s words, NCT07926737 on ClinicalTrials.gov

Coming up1

Changes1

Last 90 days

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Not yet recruiting May 2028 CMT-133 in Healthy Adult Participants
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow CMT-133

Following is part of Solo: you see every change to CMT-133 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in